Brokerages Set Outset Medical, Inc. (NASDAQ:OM) Target Price at $10.00

Shares of Outset Medical, Inc. (NASDAQ:OM) have earned an average rating of “Moderate Buy” from the five analysts that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $10.00.

Several brokerages have recently issued reports on OM. Weiss Ratings reissued a “sell (e+)” rating on shares of Outset Medical in a report on Monday, December 29th. Stifel Nicolaus dropped their price objective on Outset Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, January 7th. BTIG Research decreased their target price on Outset Medical from $17.00 to $15.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. Royal Bank Of Canada restated a “sector perform” rating and issued a $7.00 price target on shares of Outset Medical in a report on Wednesday, December 17th. Finally, Wall Street Zen lowered Outset Medical from a “hold” rating to a “sell” rating in a research report on Sunday, February 8th.

Outset Medical Stock Down 7.2%

Shares of NASDAQ OM opened at $3.35 on Monday. Outset Medical has a 52-week low of $3.00 and a 52-week high of $21.98. The company has a debt-to-equity ratio of 0.76, a quick ratio of 5.40 and a current ratio of 6.67. The stock has a market cap of $61.34 million, a P/E ratio of -0.49 and a beta of 2.12. The firm has a 50 day moving average price of $4.21 and a 200 day moving average price of $7.68.

Insider Activity at Outset Medical

In related news, General Counsel John L. Brottem sold 9,314 shares of the stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total transaction of $47,687.68. Following the completion of the sale, the general counsel directly owned 36,957 shares of the company’s stock, valued at approximately $189,219.84. This represents a 20.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Marc Nash sold 5,375 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total transaction of $27,520.00. Following the sale, the executive vice president owned 42,785 shares in the company, valued at $219,059.20. This trade represents a 11.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 40,910 shares of company stock worth $193,040. 2.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Outset Medical

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc bought a new stake in Outset Medical in the 2nd quarter valued at $34,000. Ameritas Investment Partners Inc. bought a new position in Outset Medical during the 2nd quarter worth about $35,000. BNP Paribas Financial Markets raised its stake in shares of Outset Medical by 7,013.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after purchasing an additional 2,034 shares during the period. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Outset Medical in the second quarter valued at about $78,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Outset Medical in the second quarter valued at about $108,000.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.